The product is disappearing into reorder rhythm: revenue is shifting from won-each-time to arriving-on-its-own, and the
The model's full reasoning — Q1 2017 call → NOWe need answer YES/NO based on transcript. Need determine if management describes growing share of revenue arrives without new selling event (self-arriving) and recently visibly grown proportion, grounded in observed current behavior. Need parse transcript. We need look for statements about recurring revenue, consumables, installed base, service contracts, etc. Management mentions many businesses. Need identify if they explicitly convey a recent shift in proportion of revenue from self-arriving mechanisms. Let's examine transcript. Tom Joyce opening: "We drove share gains... high-single-digit adjusted EPS growth." Mentions Pall and Cepheid performed well. "continued to reinvest..." Not directly. Later: "At Beckman Life Sciences, core revenue grew at a low-single-digit rate. Ongoing strength in Flow Cytometry and Particle Counting businesses was modestly offset by declines in certification. Developed markets was slightly softer mainly due to timing of certain projects, while strong momentum continued in China..." No. "Radiometer’s core revenue grew high-single-digits... double-digit instrument sales helped to expand Radiometer’s installed base and drive strong recurring revenue growth." This mentions installed base expansion driving recurring revenue growth. But does it convey that self-arriving share has recently and visibly grown as proportion? It says double-digit instrument sales helped expand installed base and drive strong recurring revenue growth. That implies recurring revenue growth from installed base. But is it a recent shift? It's current. However, is it "growing share of revenue now arrives without new selling event"? Radiometer has recurring revenue from consumables. But management doesn't explicitly say proportion has recently moved or that revenue is becoming less dependent on winning each sale. It's a statement about growth. "At Leica Biosystems, core revenue increased at a low-single-digit rate, led by growth in developed markets and China. Advanced staining performed very well across both instruments and consumables while core histology and tissue acquisition product lines declined." No. "Core revenue at Beckman Coulter was up low single digits, with strength in high growth markets, partially offset by weakness in Western Europe and North America.
| Ticker | Company | Call | Date | Call grade |
|---|---|---|---|---|
| DUOT | Duos Technologies Group, Inc. | Q4 2023 | 2024-04-01 | F |
| QTRX | Quanterix Corporation | Q3 2023 | 2023-11-07 | B |
| CYBR | CyberArk Software Ltd. | Q3 2021 | 2021-11-04 | B+ |
| IRBT | iRobot Corporation | Q3 2021 | 2021-10-28 | D |
| TOUR | Tuniu Corporation | Q4 2017 | 2018-03-14 | D |
DUOT · Q4 2023 → YESThe question is about whether management describes a growing share of revenue arriving without a new selling event, through reorders, renewals, etc., and that this has recently and visibly grown as a ...
QTRX · Q3 2023 → YESThe question is about whether management describes a growing share of revenue arriving without a new selling event, like through reorders, consumables, etc., and that this share has recently grown.
CYBR · Q3 2021 → YESThe question is about whether management describes a growing share of revenue arriving without a new selling event, like through renewals, and that this has recently grown as a proportion.